Contents 1. CSL Key Management Personnel 2. 2023 Key Management Personnel Remuneration Outcomes at a Glance 3. Global Remuneration Framework 4. CSL Performance and Shareholder Returns 5. Executive Key Management Personnel Outcomes in 2023 6. Executive Key Management Personnel Statutory Remuneration Tables 7. Remuneration in 2024 8. Non-Executive Director Remuneration 9. Remuneration Governance 10. Additional Employee Equity Programs and Legacy Plan Information Independent Audit of the Report The Remuneration Report for the year ended 30 June 2023 (Report) has been audited by Ernst & Young (EY). Please see page 167 of the Financial Statements for EY’s report. 1. CSL Key Management Personnel This Report sets out remuneration information for CSL’s Key Management Personnel (KMP) which includes Non-Executive Directors (NEDs), the Executive Director (i.e. the Chief Executive Officer and Managing Director (CEO)) and those key senior executives who have authority and responsibility for planning, directing and controlling the activities of CSL during the financial year (together with the Executive Director, referred to as Executive KMP). The CSL KMP during the financial year ended 30 June 2023 (2023) and changes to KMP are outlined in Table 1. Each of the KMP listed in Table 1 held their position for the full reporting period, unless stated otherwise. On 6 March 2023, Dr Paul McKenzie commenced as CEO, succeeding Mr Paul Perreault. Dr McKenzie was appointed an Executive Director on 13 December 2022. On 5 March 2023, Mr Perreault stepped down as CEO and ceased to be KMP from that date. Mr Perreault will remain with CSL as a strategic advisor until his retirement in September 2023. On 30 June 2023, CSL welcomed Mr Andrew Schmeltz who was appointed to the position of Executive Vice President CSL Behring, overseeing Commercial Development and Operations, Therapeutic Area Strategy, Market Access, Plasma Strategy and Operations, Supply Chain, Operations, Manufacturing, Procurement, Planning, Safety, and Quality across the CSL Behring business. Given the significant remit of Mr Schmeltz’s role, he will become KMP during 2024 and all remuneration details will be presented in CSL’s 2024 Remuneration Report. In 2024, Mr Bruce Brook will retire from the Board after serving four terms as a NED. Table 1: CSL Key Management Personnel in 2023 Non-Executive Directors Chairman – Dr Brian McNamee AO Mr Bruce Brook Dr Megan Clark AC Professor Andrew Cuthbertson AO Ms Carolyn Hewson AO Professor Duncan Maskell Ms Marie McDonald Ms Alison Watkins AM Executive KMP Executive Director and Chief Executive Officer and Managing Director (CEO) – Dr Paul McKenzie – from 6 March 2023 Executive Director and Chief Operating Officer (COO) – Dr Paul McKenzie – 13 December 2022 to 5 March 2023 COO – Dr Paul McKenzie – 1 July 2022 to 12 December 2022 Chief Financial Officer – Ms Joy Linton Former Executive Key Management Personnel Executive Director and Chief Executive Officer and Managing Director (CEO) – Mr Paul Perreault – 1 July 2022 to 5 March 2023 CSL Limited Annual Report 2022/23 87
RkJQdWJsaXNoZXIy MjE2NDg3